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Abstract
Background: Rotigotine is a unique dopamine agonist with activity across D1 through D5 receptors as well as
select adrenergic and serotonergic sites. This study reports the 2-year follow-up safety and efficacy data of an
ongoing open-label multicenter extension study (NCT00498186) of transdermal rotigotine in patients with
moderate to severe restless legs syndrome (RLS).
Methods: Patients received a once-daily patch application of an individually optimized dose of rotigotine between
0.5 mg/24 h to 4 mg/24 h. Safety assessments included adverse events (AEs) and efficacy was measured by the
International RLS Study Group Severity Rating Scale (IRLS), RLS-6 scales and Clinical Global Impression (CGI). Quality
of life (QoL) was measured by QoL-RLS.
Results: Of 310 patients who completed a 6-week placebo-controlled trial (SP709), 295 (mean age 58 ± 10 years,
66% females) were included in the open-label trial SP710. 64.7% (190/295 patients) completed the 2-year follow-up;
29 patients discontinued during the second year. Mean daily rotigotine dose after 2 years was 2.93 ± 1.14 mg/24 h
with a 2.9% dose increase from year 1. Rotigotine was generally well tolerated. The rate of typical dopaminergic
side effects, nausea and fatigue, was low (0.9% and 2.3%, respectively) during the second year; application site
reactions were frequent but lower than in year 1 (16.4% vs. 34.5%). The IRLS total score improved from baseline of
SP709 (27.8 ± 5.9) by 17.2 ± 9.2 in year 2 completers. Similar improvements were observed in RLS-6 scales, CGI
scores and QoL-RLS. The responder rate in the CGI change item 2 ("much” and “very much” improved) was 95%
after year 2.
Conclusions: Transdermal rotigotine is an efficacious and well-tolerated long-term treatment option for patients
with moderate to severe RLS with a high retention rate during 2 years of therapy.
Trial registration: NCT00498186
Background
Idiopathic restless legs syndrome (RLS) is a common,
chronic, and often underdiagnosed neurological sensori-
motor disorder with detrimental effects on sleep, daytime
functioning, and quality of life [1-3]. If RLS is severe and
impairs activities of daily life, a long-term therapy has to
be started and maintained over years or even life-time in
numerous patients. Recent guidelines and practice
recommendations favor the use of non-ergot dopamine
agonists over the dopaminergic agent levodopa as first-
line treatment for moderate to severe RLS [4-6]; however,
only a few prospective trials investigated longer-term effi-
cacy of open-label treatment with non-ergot dopamine
agonists for 6 months [7] or 1 year [8]. No data have yet
been published that report on stability of treatment effi-
cacy, progress of tolerability problems, requirements for
dosages of treatments, treatment complications such as
augmentation or tolerance, or the overall retention rate
on treatment during longer time periods. Here, we report
the long-term efficacy and safety results of an ongoing
trial after 2 years of rotigotine treatment.
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activity at D1 through to D5 receptors and at selected
serotonergic and adrenergic receptors [9]; it has been
formulated as a silicone-based transdermal patch for
once-daily application to provide continuous drug deliv-
ery and stable plasma concentrations over a 24-h period.
Rotigotine transdermal patch has been successfully used
in the treatment of Parkinson’s disease (PD) [10,11].
The transdermal delivery of a dopamine agonist is a
new treatment option for RLS. Proof-of-concept for the
rotigotine patch in patients with moderate to severe,
idiopathic RLS was successfully demonstrated in a 1-
week pilot trial [12], and efficacy and good tolerability
was shown in a 6-week dose-finding trial [13] and in
two 6-month randomized, placebo-controlled, fixed-dose
trials conducted in Europe and the US [14,15]. To assess
long-term rotigotine safety and efficacy, patients com-
pleting the dose-finding trial [13] were offered the possi-
bility of entering an open-label extension. Data from the
initial placebo-controlled trial [13] and from the first
year of the open-label follow-up [16] showed stable,
clinically relevant improvements in all efficacy measures.
Methods
Trial design
This multicenter, multinational, single-arm, open-label
extension trial (NCT00498186) started in July 2003 in 33
hospital outpatient units, sleep centers, or private neurol-
ogy practices in three European countries (Austria,
Germany, and Spain) and is still ongoing. It is being con-
ducted according to the Declaration of Helsinki, Good
Clinical Practice, and local regulations in each country.
The trial protocol and amendments were reviewed and
approved by a central institutional review board in Ger-
many (Kommission für Ethik in der ärztlichen Forschung
im Fachbereich Humanmedizin der Philipps-Universität
Marburg) and in Austria (Ethikkommission der Medizi-
nischen Universität Innsbruck). Review and approval was
provided by regional institutional review boards in Spain.
Written informed consent was obtained from all subjects
prior to inclusion in the trial.
The trial design was described in the presentation of
the first year trial data [16]. Briefly, following wash-out
of the double-blind medication, rotigotine was up-
titrated from a starting dose of 0.5 mg/24 h to a maxi-
mum dose of 4 mg/24 h according to the individual
requirements of the patients with intermediate steps of
1 mg/24 h, 2 mg/24 h, or 3 mg/24 h. The patch was
administered once-daily in the morning using rotating
application sites within 14 days of treatment. During the
trial, patients remained on their optimum dosage; how-
ever, dose adjustments were allowed for efficacy or tol-
erability reasons at the discretion of the investigators.
Patients were withdrawn if higher doses than the
maximum of 4 mg/24 h rotigotine were required. Visits
throughout the maintenance phase were scheduled at 3-
monthly intervals during the second trial year. In the
event of premature discontinuation, a 1-week taper per-
iod and a 2-week surveillance period for safety follow-
up was planned.
Outcome measures
Safety and tolerability were determined by adverse event
(AE) documentation, patch application site assessment,
changes in vital signs, body weight, 12-lead electrocar-
diogram (ECG), and safety laboratory parameters
throughout the second trial year. ‘Global rating of toler-
ability by the subject’ was assessed using a 5-point scale
(1 = ‘very good’ to 5 = ‘very bad’); Clinical Global
Impressions (CGI) item 4 ‘side effects’ (1 = none to 4 =
outweighs therapeutic effect) [17] and the Epworth Slee-
piness Scale (ESS) [18] were also evaluated. In addition,
the rate of patients who completed the entire 2 years of
long-term treatment (retention rate), as well as the rate
and reasons of those patients who prematurely withdrew
from the trial, were assessed. Patch adhesiveness was
also evaluated using a patient questionnaire.
When the study was commenced, no validated tool for
diagnosis and severity assessment for augmentation was
available. Augmentation, could, however, be reported as
a reason for dose adjustment.
Efficacy was evaluated using the total score of the
International RLS Study Group Severity Rating scale
(IRLS) [19], the RLS-6 scales to assess severity of RLS
symptoms at different time periods, quality of sleep and
daytime sleepiness [20], and the CGI to assess severity of
symptoms, global change of condition, and therapeutic
effect [17]. In addition to the analysis of changes from
baseline in these variables, treatment responders were
d e f i n e db yas c o r ei m p r o v e m e n to fa tl e a s t5 0 %f o rt h e
IRLS total score or CGI-1 at the end of the 2-year main-
tenance phase compared with baseline; a CGI-2 respon-
der had a rating of ‘much’ or ‘very much improved’ at the
end of year 2. A remitter was defined by an IRLS score of
10 or less at the end of year 2; the proportion of patients
presenting with no symptoms at the end of year 2 (IRLS
score = 0) was also calculated (symptom free). ‘Global
rating of efficacy by the subject’ was assessed using a 5-
point scale (’very good’ to ‘very bad’) and quality of life
(QoL) was evaluated with the total score of the QoL-RLS
questionnaire [21].
Patients
Patients completing the double-blind phase of the pre-
ceding dose-finding trial [13] were offered participation
in this open-label extension. They were not permitted to
participate if serious adverse events (SAEs) were
ongoing that were suspected to be related to the
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ders had occurred, or if they had not been compliant
during the double-blind trial. A full description of the
inclusion and exclusion criteria to enter the preceding
trial can be found elsewhere [13].
Statistical analysis
The present paper reports the 2-year interim data analy-
sis of a 5-year trial. By nature of an interim analysis,
some of the end of year 1 data in the present paper may
differ slightly from the published year 1 analysis [16].
All patients treated with at least one dose of trial
medication were included in the safety analysis; patients
analyzed for efficacy had to have at least one efficacy
value during the long-term extension trial (intention-to-
treat [ITT]). Analyses included changes in variables
from baseline to end of year 2 and changes from end of
year 1 to end of year 2. If not otherwise stated, the base-
line data of the preceding dose-finding trial for all
patients entering the open-label trial (n = 295) were
used [13]. All variables were analyzed descriptively
b a s e do no b s e r v e dc a s e sp e rv i s i t ;t h eu s eo ft h e‘Last
Observation Carried Forward’ (LOCF) approach for
some efficacy variables is indicated with the data. With
respect to the validity of the efficacy variables, only
those measures that were taken within 2 days of the last
patch application were used.
Results
Of a total of 295 patients entering the open-label trial,
220 patients completed the first trial year (retention rate
74.6%) and 191 patients completed the second trial year
resulting in an overall retention rate of 64.7% after 2
years of treatment.
Mean age of the study population (n = 295) was
58.3 ± 10.1 years (range 22-75) at baseline with 66% of
female gender. Patients had a long history of RLS symp-
toms; a large proportion had received pretreatment with
dopaminergic drugs [13]. Baseline values of the IRLS
total score (27.8 ± 5.9) indicated severe RLS on average;
mean severity of daytime symptoms at rest in the RLS-6
scales was 4.9 ± 2.6 (range 0 = no symptoms, 10 = very
severe symptoms).
Eighty-seven percent of the patients completing year 1
also completed year 2. Reasons for premature disconti-
nuation during titration, the first, and second trial year
are summarized in Table 1.
Treatment
The mean duration of rotigotine exposure was 556 ±
256 days (median 700 days). The majority of the
patients (94%) were compliant during maintenance
(defined as ≥85% and ≤115% application of the planned
number of patches). Withdrawal for noncompliance was
documented for two patients in year 1 and two patients
in year 2.
Individually optimized flexible doses ranged from 0.5
mg/24 h (2.5 cm
2 patch) to 4 mg/24 h (20 cm
2 patch).
The most frequently applied dose at the end of year 2
was 4 mg/24 h (44.5% of all patients). The number of
patients sufficiently treated with a dose of 0.5 or 1 mg/
24 h (13.5%) decreased by 1.3% from year 1. The aver-
age daily dose during the maintenance phase showed a
slight increase from 2.85 ± 1.15 mg/24 h in year 1 to
2.93 ± 1.14 mg/24 h in year 2. Figure 1 shows the mean
daily rotigotine dose over 24 months of maintenance.
Dose adjustment was not required for 43.8% of patients
during the 2-year maintenance; doses were adjusted
once in 29% and twice in 16.9% of the patients. The
remaining 10.3% needed 3 to 5 dose adjustments during
maintenance. Of all patients entering year 2, 88% main-
tained their dose during year 2.
Safety outcomes
During the trial, 256 patients (87%) experienced at least
one AE. The majority of AEs were mild or moderate in
intensity; events were rated as severe in 22% of the
patients.
Adverse events were documented for 75.2% of the
patient population during the first trial year [16] and for
59.6% during the second year. Table 2 summarizes all
incidences reported in more than 3% of all patients over
the 2-year period. Application site disorders occurred
most frequently; they were considered severe for 8.8% of
the patients. More patients were affected by application
site reactions during the first trial year (n = 100, 34.5%)
whereas 16.4% (n = 36) reported them in the second
year (25 patients [8.5%] had application site reactions
ongoing from the preceding dose-finding study [13]).
Discontinuation owing to any application site disorder
was reported for 9.3% of patients (n = 27) in the first
and 3.6% (n = 8) in the second trial year. The incidence
Table 1 Reasons for premature discontinuation
Number of patients (%)
Titration
(n = 295)
Year 1
(n = 290)
Year 2
(n = 220)
Patients withdrawn 5 (1.7) 70 (24.1) 29 (13.2)
Owing to
Adverse event 4 (1.4) 47 (16.2) 16 (7.3)
Withdrawal of
consent
1 (0.3) 6 (2.1) 2 (0.9)
Lack of efficacy 0 10 (3.5) 7 (3.2)
Protocol deviation 0 4 (1.4) 0
Unsatisfactory
compliance
0 2 (0.7) 2 (0.9)
Lost to follow-up 0 1 (0.3) 0
Other reasons 0 0 2 (0.9)
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Page 3 of 10of somnolence (2 cases), depression (5), syncope (1),
insomnia (1), parasomnias (2), diarrhea (2), hypertension
(4), and dry mouth (2) was low and sleep attacks, hallu-
cination, dizziness, paraesthesia, and vomiting did not
occur during year 2. During the second year, 21 patients
(9.5%) experienced a total of 22 SAEs; none were con-
sidered to be related to trial medication. With the
exception of localized osteoarthritis (4 patients), uterine
leiomyoma (3), syncope (2), and goitre (2), all SAEs
occurred only in single patients during the 2-year treat-
ment period (for complete list of SAEs see Additional
file 1). No deaths were reported in the 2-year study
period.
There were no major changes from double-blind base-
line in any of the laboratory parameters including total
iron and ferritin levels. There were no patients with any
post-baseline QTc ≥500 ms or post-baseline increase in
QTc ≥60 ms in the ECG during the trial period.
Tolerability outcomes
The ‘daytime tiredness’ score (RLS-6 scales) improved
from a double-blind baseline score of 4.8 ± 2.6 by -2.6 ±
3.1 in the first year and by -2.2 ± 3.0 in the second year
resulting in a total score of 2.5 ± 2.4 after 2 years of
rotigotine treatment (Table 3; negative changes in the
table refer to improvements). The total ESS score
improved from 6.7 ± 5.2 at double-blind baseline by
-0.6 ± 4.6 after 2 years (Table 3).
Based on CGI tolerability rating, a total of 70% of the
220 patients completing year 1 and 71% of the 191
patients completing the second trial year were not
impaired by side effects at all; 28.1% of the year 1 com-
pleters and 28.3% of the year 2 completers reported that
side effects did not significantly interfere with their daily
activities. At the end of the 2-year period, a ‘significant
interference’ and ‘side effects outweighing efficacy’ were
reported in 13% and 6.8%, respectively, of all patients
who had entered the trial.
Rotigotine tolerability after 2 years of treatment was
rated as ‘very good’ or ‘good’ by 77% of all patients (n =
295). Seventeen patients (5.8%) described tolerability as
‘very bad’.
Patch adhesiveness and ease of removal were consid-
ered moderate (15%/4.5%), good (50%/58%), or excellent
(31%/34%) by most patients treated in year 2 (n = 220).
Efficacy
Rotigotine transdermal patch rapidly improved the IRLS
severity rating; the baseline sum score of 27.8 ± 5.9 was
reduced by 18.8 ± 8.6 during the 4-week titration phase
of the open-label trial (Figure 2). This result is compar-
able to the data recorded during rotigotine titration in
the preceding double-blind, placebo-controlled trial [13].
Figure 3 shows the changes in IRLS severity over 2
years of rotigotine treatment. At month 12 and month
24, mean IRLS sum scores of 8.7 ± 8.0 and 10.3 ± 9.3,
Figure 1 Mean daily rotigotine dose over the 2-year maintenance period (safety population).
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years of rotigotine maintenance treatment was 15.4 ±
10.3 for all patients entering this extension trial (n =
295, LOCF) and 17.2 ± 9.2 for all patients completing
the 2-year period (n = 190). CGI-1 and RLS-6 daytime
at rest scores closely follow this pattern (Figure 2). All
other efficacy variables also improved over the 2-year
period (Table 3) and remained stable during the second
year when compared with the year 1 results [16].
Responder rates indicate that the majority of patients
benefited from rotigotine treatment (Table 4). Overall,
30% of all patients who completed the 2-year treatment
were free of symptoms according to IRLS (total score =
0) and 30% were free of symptoms according to CGI-1
(not ill at all). Therapeutic efficacy of rotigotine was
rated as ‘good’ to ‘very good’ in 95% (n = 209) of year 1
completers and 89% (n = 170) of year 2 completers.
Discussion
Rotigotine transdermal patch is the first transdermally
applied dopamine agonist for the treatment of symp-
toms of RLS and covers a 24-h period with a single
administration. The continuous rotigotine delivery
seems to translate into long-term benefits for patients
moderately to severely affected by RLS. Over a period of
2 years, a rotigotine dose range of 0.5 mg/24 h to 4 mg/
24 h provided sustained relief from symptoms with a
very good tolerability and a favorable safety profile.
Rotigotine dose levels remained quite stable from the
first to the second trial year with only a small dose
increase of 2.9% for a mean daily dose of 2.93 mg/24 h
after 2 years of treatment. The most frequently applied
rotigotine dose at the end of 2 years was 4 mg/24 h
(44.5% of patients); 13.5% were sufficiently treated with
a low dose of 0.5 or 1.0 mg/24 h. In the preceding
6-week dose-finding trial with a fixed dosing schedule,
Table 3 Improvement in efficacy over a 2-year maintenance treatment with transdermal rotigotine: Mean change from
baseline; mean ± SD or number (%)
Baseline of
double-blind
study
Change at end
of year 1
(as observed)
Change at end
of year 1
(LOCF)
Change at end
of year 2
(as observed)
Change at end
of year 2
(LOCF)
N Score N Score Score N Score Score
IRLS total score 295 27.8 ± 5.9 220 -18.8 ± 8.8 -17.4 ± 9.9 190 -17.2 ± 9.2 -15.4 ± 10.3
RLS-6
Satisfaction with sleep 293 7.2 ± 2.5 216 -4.5 ± 3.4 -4.1 ± 3.5 190 -4.3 ± 3.3 -3.7 ± 3.4
Severity at bedtime 293 6.0 ± 3.0 215 -4.6 ± 3.2 -4.2 ± 3.3 189 -4.0 ± 3.1 -3.8 ± 3.2
Severity during the night 294 6.8 ± 2.7 216 -5.2 ± 3.0 -4.9 ± 3.1 190 -4.9 ± 3.0 -4.5 ± 3.2
Severity during the day when
resting
293 4.9 ± 2.6 216 -3.4 ± 2.6 -3.4 ± 2.7 190 -2.9 ± 2.7 -2.9 ± 3.0
Severity during the day when
active
294 1.9 ± 2.0 217 -1.4 ± 1.9 -1.5 ± 2.0 190 -1.2 ± 2.0 -1.2 ± 2.2
Daytime tiredness or sleepiness 294 4.8 ± 2.6 217 -2.8 ± 2.9 -2.6 ± 3.1 190 -2.4 ± 2.7 -2.2 ± 3.0
CGI-1 (severity of illness) 295 5.1 ± 0.9 217 -2.9 ± 1.2 -2.8 ± 1.3 191 -2.8 ± 1.2 -2.6 ± 1.4
QoL-RLS total score 273 30.2 ±
10.4
200 -19.1 ±
12.2
-17.7 ± 13.2 178 -17.7 ±
12.8
a
-15.8 ± 13.8
a
ESS total score 289 6.7 ± 5.2 215 -1.5 ± 4.5 n.d. 185 -0.8 ± 4.6 -0.6 ± 4.6
a after 21 months of maintenance.
Table 2 Incidence of adverse events (AEs) reported in
≥3% of all patients during the 2-year maintenance
(safety population)
Number of patients (%)
Year 1 (n = 290) Year 2 (n = 220)
Patients with AEs 218 (75.2) 131 (59.6)
Number of AEs 630 263
Most frequent AEs
a
Any application site
disorder
b
100 (34.5) 36 (16.4)
Nasopharyngitis 25 (8.6) 9 (4.1)
Back pain 20 (6.9) 10 (4.5)
Erythema 19 (6.6) 2 (0.9)
Nausea 14 (4.8) 2 (0.9)
Pruritus 11 (3.8) 2 (0.9)
Insomnia 11 (3.8) 1 (0.5)
Hypertension 10 (3.4) 4 (1.8)
Fatigue 9 (3.1) 5 (2.3)
Bronchitis 9 (3.1) 5 (2.3)
Sleep disorder 9 (3.1) 5 (2.3)
Patients with serious AEs 21 (7.2) 21 (9.5)
Number of serious AEs 24 22
a Incidence in ≥3% of all patients.
b Includes preferred terms application site
erythema, application site reaction, application site pruritus, and other related
terms with lower frequency (e.g., inflammation).
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Page 5 of 10Figure 2 Mean IRLS total score, CGI item 1 (severity of illness), and RLS-6 item 4 (severity during the day at rest) scores over 2 years
of rotigotine maintenance treatment (data as observed). B, baseline; CGI, Clinical Global Impression; IRLS, International RLS Severity Scale;
RLS, restless legs syndrome S, start of maintenance phase.
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Page 6 of 10the 4 mg/24 h dose did not show an additional benefit
compared with 3 mg/24 h over the 6-week treatment
period. The likely therapeutic window for the treatment
of idiopathic moderate to severe RLS was thus estab-
lished as ranging from 1 mg/24 h to 3 mg/24 h [13].
The distribution of individual rotigotine doses in this
trial supports the opinion of most RLS experts that dose
selection has to be adjusted according to efficacy and
tolerability experiences of each individual patient and
dosages of rotigotine both lower or higher than the
recommended doses of 1 mg/24 h or 3 mg/24 h may be
appropriate during long-term rotigotine therapy.
Discontinuation rates owing to a lack or loss of effi-
cacy through 2 years of rotigotine treatment were low
Figure 3 Changes in IRLS severity over 2 years of rotigotine maintenance treatment (data as observed).
Table 4 Improvement in efficacy over a 2-year maintenance treatment with transdermal rotigotine: responder and
remitter rates compared with baseline
End of year 1 End of year 2
As observed (n = 217) n = 295 As observed (n = 190) n = 220
IRLS total score
Responder (≥50% improvement) 75% 68% 65% 79%
Remitter (total score ≤10) 60% 54% 53% 62%
Symptom-free (total score = 0) 30% 25% 30% 32%
CGI-1 responder (≥50% improvement) 79% 72% 75%
a 65%
CGI-2 responder (’much’ or ‘very much’ improved) 97% 89% 95%
a 85%
a n = 191.
CGI, Clinical Global Impression; ESS, Epworth Sleepiness Scale; IRLS, International RLS Severity Scale; QoL, quality of life; RLS, restless legs syndrome
Range of scales: IRLS: 0 to 40 (= severe), RLS-6: 0 to 10 (= severe); CGI-1: 1 to 7 (= extremely severe), QoL-RLS: 0 to 60 (= severe impairment).
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duration are available for other dopamine agonists. Dis-
continuation rates for studies of shorter duration are as
follows: 3.3% within 6 months [22] and 7.9% within 30
weeks [23] of treatment with cabergoline, and 3.5%
within 52 weeks of treatment with ropinirole [8]. Open-
label treatment with pramipexole for 26 weeks did not
lead to withdrawal for efficacy reasons [7].
Augmentation, the main complication of long-term
dopaminergic treatment in RLS [24], is mainly charac-
terized by an earlier appearance of RLS symptoms in
the day and an overall increase in the severity of RLS
symptoms. Augmentation was given as the reason for
seven dose adjustments - a low occurrence of 2.4% over
2 years. In the absence of any validated diagnostic tool
for the diagnosis of augmentation at the start of the
study, a detailed retrospective analysis by an expert
panel is planned following completion of the full 5-year
observation period.
Known dopaminergic side effects such as nausea and
fatigue occurred mainly during titration and the first
study year [16]. Incidences during the first year were
similar to the rates reported in open-label long-term
trials for cabergoline (6 months) [22] and pramipexole
(26 weeks) [7] but lower than for ropinirole (52 weeks)
[8]. During the second year, only two cases of nausea
and five cases of fatigue were documented, and vomiting
was not reported as an AE. The incidence of somno-
lence was also lower in year 2 (two cases compared with
five cases in year 1), and hallucinations, dizziness, and
sleep attacks were not reported.
As expected with a transdermal application, skin reac-
tions were common with higher rates in the first (34.5%,
100/290 patients) compared with the second (16.4%, 36/
220) trial year. Most cases were mild to moderate in
intensity. However, a proportion of patients discontin-
ued owing to application site problems: 27 patients left
the study in year 1 and 8 patients in year 2. Similar or
higher discontinuation rates of patch treatments were
reported for other indications [25,26].
Investigators noted ‘much’ and ‘very much’ improve-
ment of RLS in 95% of all patients who had entered this
open-label extension. The severity of the condition as
measured with the IRLS already improved during the
titration period, remained stable during the first trial
year [16] and only slightly increased during the second
year. More than half of the patients completing the
study were regarded as remitters (53%) and 30% were
symptom-free after 2 years of rotigotine treatment.
Responder rates underline the sustained, long-term ben-
efit of the rotigotine transdermal patch. The improve-
ment in QoL paralleled by the improvement of RLS
symptoms during the night as well as during the day (as
shown in the RLS-6 scales) supports the benefit of deliv-
ery of rotigotine over 24 hours in the treatment of RLS.
The good long-term efficacy and safety profile of
transdermal rotigotine resulted in high retention rates:
after 2 trial years it was 66%, and 87% of the patients
entering the second year completed 2 years of mainte-
nance. Compliance in the second year was still 92% and
the majority of the patients rated tolerability and efficacy
of the treatment as ‘good’ or ‘very good’. Treatment
satisfaction is also underlined by the QoL-RLS score
which was improved by 50% at the end of the 2-year
follow-up from baseline of the double-blind trial [13].
In interpreting these long-term open-label data, it is
important to note the limitation presented by the
absence of a comparator arm; however, inclusion of a
placebo group for 2 years of follow-up is inappropriate
both practically and ethically. In the preceding 6-week,
double-blind study a reduction in IRLS score of 9.2
points from baseline was observed in the group of
patients randomized to placebo [13]. The 15- to
17-point reduction observed with open-label rotigotine
is consistent with the reductions achieved with rotigo-
tine doses of 1-4 mg/24 h during the double-blind
study. Although these open-label data support the
assumption of a symptomatic benefit over a 2-year per-
iod, the net effect on IRLS reduction with rotigotine is
likely less than the 15-17 points reported here.
Putting both efficacy and tolerability results into per-
spective, the 2-year data of the rotigotine trial indicate a
selection process: patients who do not tolerate either
t h ed o p a m i n ea g o n i s to rt h ep a t c ha d m i n i s t r a t i o n ,o r
both, generally discontinue treatment during the first
year of therapy. Perceived loss of efficacy is not a major
issue during long-term therapy with rotigotine in the
great majority of the patients. Thus a high number of
patients who stayed on therapy benefited from rotigo-
tine as expressed in the fact that 30% of patients (57 of
190 patients) were free of symptoms after 2 years.
Conclusions
The findings of this trial suggest that long-term admin-
istration of rotigotine transdermal patch is generally
well tolerated and an efficacious treatment option for
patients with moderate to severe RLS. The treatment
markedly improved RLS symptoms and quality of life of
the patients.
Appendix
Rotigotine SP710 Study Group
Austria: W. Poewe/B. Högl (Innsbruck), B. Saletu
(Vienna).
Germany: H. Benes (Schwerin), B. Bergtholdt (Berlin),
R. Bodenschatz (Mittweida), P. Clarenbach (Bielefeld), I.
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Page 8 of 10Eisensehr (Munich), P. Franz (Berlin), P. Geisler
(Regensburg), U. Hegerl (Nuremberg), W. Käfferlein
(Bamberg), M. Lang, (Ulm) G. Karlbauer (Munich), S.
Krämer (Berlin), I. Maier (Tuttlingen), G. Mayer
(Schwalmstadt-Treysa), W. Oertel/K. Stiasny-Kolster
(Marburg), C. Öhlwein (Gera), I. Peglau (Berlin), K. Sal-
lach (Gelsenkirchen), K. Schlinsog (Halle), T. Schwerdt-
feger (Naumburg), A. Schulze (Berlin), A. Siever
(Oldenburg), K. Sigel (Munich), H. Sommer (Koethen),
K. Tinschert (Jena), C. Trenkwalder (Kassel/Göttingen),
B. Veit (Neubrandenburg), R. Warmuth (Berlin).
Spain: E. Estevil (Barcelona), D. Garcia-Borreguero
(Madrid), F. Puertas (Valencia).
Additional material
Additional file 1:
Further SAEs occurring in single patients only.
This file contains a list of the SAEs which occurred
in single patients only during the 2-year treatment
period
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